Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma

Fig. 2

The generation of heterobivalent Nb21/Nb66. A The affinity of 11 IL-5 Nbs was detected by biofilm interferometry (BLI). B The recognition specificity of 11 IL-5 Nbs to different species antigens was determined by ELISA, with IgG1 as a negative control. C The competition binding activity of Nb66 or Nb21 towards the binding between Nb21-biotin and IL-5 or Nb66-biotin and IL-5 was detected by ELISA. D The recognition specificity of Nb21/Nb66 towards Nb21-biotin-IL-5 or Nb66-biotin-IL-5 binding sites, with IL33-Nb biotin as a negative control. The experiments were performed in triplicate. The data were presented as mean ± SD. ***P < 0.001. E The blocking effect of the Nb21/Nb66 or Nucala analogue on the interaction between IL-5 and IL-5R was determined by flow cytometry. MFI: median fluorescence intensity. F The inhibitory effect of the Nb21/Nb66 or Nucala analogue on TF-1-cells proliferation was determined by the CCK8 assay. The IC50 was calculated

Back to article page